Yves Briers will head up Obulytix, a new company based on the phage lysin-based platform leveraging AI to tackle bacterial infections he co-developed at Ghent University and KU Leuven. Obulytix has already attracted $4 M Euro investment from Boehringer Ingelheim Venture Fund, Qbic, and Gemma Frisius Fund.